VEEV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now, but treat it as a “near-support rebound” entry rather than a momentum buy. VEEV is in a short-term downtrend, yet it’s trading very close to a key support zone (~201.6–207.2) with deeply oversold short-term RSI and bullish options positioning (low put/call ratios). Fundamentals and recent product news remain constructive, and Wall Street is still broadly positive despite recent price-target trims. For an impatient buyer, the current pullback offers a reasonable entry point versus waiting for a perfect setup.
Trend/Momentum: Bearish near-term. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), signaling a broader downtrend. MACD histogram is negative (-1.171) and expanding lower, confirming downside momentum is still active.
Oversold condition: RSI_6 at ~20.7 indicates the stock is oversold in the very short term, which often increases odds of a bounce—especially near support.
Key levels: Current price 203.66 is below the pivot (216.29) and sitting just above S2 (201.56) and below S1 (207.19). This places price in a support pocket; a clean break below ~201.6 would be technically negative, while a reclaim of ~207 and then the pivot ~216 would improve the chart.
Near-term probability (pattern-based): Model suggests slightly negative next day (-0.57%) but modestly positive over 1 week (+1.56%) and 1 month (+1.14%), consistent with “down now, bounce later” behavior.
on 2026-03-02 after hours (EPS est. 1.36). If execution remains strong, this can be a sentiment reset after the recent pullback.
Technical pressure: Trend is still down (bearish MA stack + negative, widening MACD). Oversold can stay oversold if the market continues risk-off.
Multiple/valuation compression risk: Several price-target cuts cite software multiple compression (a market-driven headwind even if fundamentals are fine).
Event risk into earnings: With elevated implied volatility, the market is pricing larger-than-normal moves around catalysts (including earnings).
Latest reported quarter: FY2026/Q3.
Growth: Revenue 811.236M, +16.02% YoY (solid mid-teens growth). Profitability improved with Net Income 236.203M, +27.12% YoY and EPS 1.40, +23.89% YoY.
Margins: Gross margin 75.41% (+0.47 YoY), indicating strong/steady unit economics.
Takeaway: Fundamentals show accelerating profitability vs revenue growth (operating leverage), supportive of buying dips when the chart is oversold.
Recent trend (ratings/targets): Ratings are mostly constructive (Buy/Outperform/Overweight common), but many targets were trimmed since late 2025, largely attributed to sector multiple compression rather than a fundamental breakdown. Notably, Truist upgraded to Buy (2026-01-08, PT $275), while Baird lowered PT to $283 but maintained Outperform.
Wall Street pros: Durable moat in life sciences software, expanding suite (Vault/clinical/data), improving product-led narrative, early AI traction, and solid growth with margin stability.
Wall Street cons: Limited near-term multiple expansion, lingering CRM/migration-related uncertainties (timing/optics), and sensitivity to broader software valuation cycles.
Influential/political trading: No recent congress trading data available; hedge funds and insiders are reported as neutral with no significant recent trend.
